



**Press release**

June 17, 2024

**Appointment of Representative Director (Chief Financial Officer)**

BTB Therapeutics Co., Ltd. (Representative Director: Tsuyoshi Ogiku, Registered Office: Kyoto, Japan) announces the appointment of Takashi Kiyozumi as Representative Director (Chief Financial Officer) on June 10, 2024.

**About BTB Therapeutics Co., Ltd.:**

BTB Therapeutics Co., Ltd. was established in June 2020 based on the drug discovery programs of Professor Masatoshi Hagiwara of Kyoto University. We are engaged in the research and development of ENDOPIN, a First-in-Class non-opioid analgesics, as well as small molecules targeting abnormal RNA splicings for the treatment of rare diseases and cancer immunotherapy. Our goal is to create innovative new drugs to address unmet medical needs. Since our inception, we have been awarded multiple grants from the Japan Agency for Medical Research and Development (AMED) and Kyoto Prefecture, totaling approximately 5 billion yen in public financial support.

Representative Directors: Tsuyoshi Ogiku and Takashi Kiyozumi

Date of establishment: June 29, 2020

Website: <https://btb-newdrug.co.jp/en>

For inquiries regarding this release, please contact: [info@btb-newdrug.co.jp](mailto:info@btb-newdrug.co.jp)